Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

iPLEDGE gets another committee review

Executive Summary

FDA's Dermatologic and Ophthalmic Drugs Advisory Committee will meet Aug. 1 to provide updates on risk management activities for the acne therapy isotretinoin (Roche's Accutane and generics). The iPLEDGE program requires manufacturers of the product to submit reports to FDA to ensure drug exposure during pregnancy is minimized (1"The Pink Sheet" Aug. 22, 2005, p. 14). Implementation of iPLEDGE sparked frequent complaints to the Center for Drug Evaluation and Research Ombudsman's office last year, causing the program's effectiveness to be questioned (2"The Pink Sheet" March 5, 2007 p. 9)...

You may also be interested in...



Accutane iPLEDGE Program Tops CDER Ombudsman’s 2006 Complaint List

The most frequent complaint to the Center for Drug Evaluation & Research Ombudsman's office in 2006 concerned implementation of the iPLEDGE program, the office said in its annual report, issued Feb. 28

FDA Requires Multiple Reports On New Accutane Risk Management Program

FDA is requiring manufacturers of the acne therapy isotretinoin (Roche's Accutane and generics) to submit multiple reports to the agency on the effectiveness of the product's new risk management program iPLEDGE

Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%

Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics. 

UsernamePublicRestriction

Register

LL1135307

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel